Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis : A Danish Nationwide Study. / Loft, Nikolai Dyrberg; Egeberg, Alexander; Rasmussen, Mads Kirchheiner; Bryld, Lars Erik; Gniadecki, Robert; Dam, Tomas Norman; Iversen, Lars; Skov, Lone.
In: Acta Dermato-Venereologica, Vol. 99, No. 13, 10.2019, p. 1224-1230.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis
T2 - A Danish Nationwide Study
AU - Loft, Nikolai Dyrberg
AU - Egeberg, Alexander
AU - Rasmussen, Mads Kirchheiner
AU - Bryld, Lars Erik
AU - Gniadecki, Robert
AU - Dam, Tomas Norman
AU - Iversen, Lars
AU - Skov, Lone
PY - 2019/10
Y1 - 2019/10
N2 - The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based on data from the Danish national registry (DERMBIO), this study investigated the correlation between changes in PASI and DLQI in a cohort of patients with moderate-to-severe psoriasis treated with biologics or apremilast using Spearman’s rank correlation analyses. The correlation analysis of 1,677 patients, of whom 276 had available data after 5 years, showed weak-to-moderate correlation between PASI and DLQI during a 5-year period and between changes in PASI and DLQI: 0.58 (p < 0.0001) for baseline to 3 months and 0.42 (p < 0.0001) for 3 to 12 months. The first question on “Symptoms and feelings” made up the largest proportion of the overall DLQI. The correlation between PASI and DLQI is weakto-moderate and varies over time. Changes in PASI correlate weak-to-moderately with changes in DLQI during the first 12 months of treatment, with symptoms being the most important factor contributing to impaired quality of life.
AB - The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based on data from the Danish national registry (DERMBIO), this study investigated the correlation between changes in PASI and DLQI in a cohort of patients with moderate-to-severe psoriasis treated with biologics or apremilast using Spearman’s rank correlation analyses. The correlation analysis of 1,677 patients, of whom 276 had available data after 5 years, showed weak-to-moderate correlation between PASI and DLQI during a 5-year period and between changes in PASI and DLQI: 0.58 (p < 0.0001) for baseline to 3 months and 0.42 (p < 0.0001) for 3 to 12 months. The first question on “Symptoms and feelings” made up the largest proportion of the overall DLQI. The correlation between PASI and DLQI is weakto-moderate and varies over time. Changes in PASI correlate weak-to-moderately with changes in DLQI during the first 12 months of treatment, with symptoms being the most important factor contributing to impaired quality of life.
KW - Biologics
KW - Dermatology Life Quality Index
KW - Patient-reported outcomes
KW - Psoriasis
KW - Psoriasis Area and Severity Index
U2 - 10.2340/00015555-3331
DO - 10.2340/00015555-3331
M3 - Journal article
C2 - 31580465
AN - SCOPUS:85076584683
VL - 99
SP - 1224
EP - 1230
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
IS - 13
ER -
ID: 241580249